We are live on ! Find out more
BC

Boxer Capital Portfolio holdings

AUM $2.04B
1-Year Est. Return 108.39%
This Fund
S&P 500
This Quarter Est. Return
+26.13%
1 Year Est. Return
+108.39%
3 Year Est. Return
+261.8%
5 Year Est. Return
+1,135.09%
10 Year Est. Return
–
AUM
$2.02B
AUM Growth
+$18.4M
Cap. Flow
-$139M
Cap. Flow %
-6.88%
Top 10 Hldgs %
53.81%
Holding
65
New
13
Increased
7
Reduced
4
Closed
6

Top Buys

Rank Stock Value
1
FATE icon
Fate Therapeutics
FATE
+$47.8M
2
NKTX icon
Nkarta
NKTX
+$43.3M
3
AMLX icon
Amylyx Pharmaceuticals
AMLX
+$19.6M
4
KURA icon
Kura Oncology
KURA
+$19.4M
5
ALLO icon
Allogene Therapeutics
ALLO
+$16.1M

Top Sells

Rank Stock Value
1
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$188M
2
IMGN
Immunogen Inc
IMGN
+$87.8M
3
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$79.1M
4
ARGX icon
argenx
ARGX
+$23.2M
5
IOVA icon
Iovance Biotherapeutics
IOVA
+$7.57M

Sector Composition

Rank Sector Weight
1 Healthcare 99.87%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BDTX icon
51
Black Diamond Therapeutics
BDTX
$101M
$2.57M 0.13%
506,000
– –
LABD icon
52
Direxion Daily S&P Biotech Bear 3X ETF
LABD
$66.3M
$2.55M 0.13%
+35,000
New +$2.92M
BCAB icon
53
BioAtla
BCAB
$5.59M
$2.36M 0.12%
13,727
– –
OBIO icon
54
Orchestra BioMed
OBIO
$228M
$1.26M 0.06%
238,193
– –
TARA icon
55
Protara Therapeutics
TARA
$227M
$839K 0.04%
209,227
– –
MIST icon
56
Milestone Pharmaceuticals
MIST
$144M
$553K 0.03%
309,007
– –
DBVT
57
DBV Technologies
DBVT
$810M
$375K 0.02%
50,000
– –
NUVB.WS
58
DELISTED
Nuvation Bio Inc Warrants
NUVB.WS
$80.7K ﹤0.01%
266,666
– –
SRZNW icon
59
Surrozen Inc Warrant
SRZNW
$76.2K
$2.17K ﹤0.01%
66,666
– –
KOD icon
60
Kodiak Sciences
KOD
$2.62B
– –
-600,000
Closed -$1.82M
BCEL
61
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
– –
-2,202,333
Closed -$291K
KRTX
62
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
– –
-250,000
Closed -$79.1M
IMGN
63
DELISTED
Immunogen Inc
IMGN
– –
-2,961,000
Closed -$87.8M
RAIN
64
DELISTED
Rain Oncology Inc. Common Stock
RAIN
– –
-1,152,212
Closed -$1.38M
MRTX
65
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
– –
-3,201,440
Closed -$188M
1 2
3

Similar funds

FTDI
First Trust Direct Indexing Boston, Massachusetts $1.87B AUM 43.63% 1-Year Est. Return
CIM
Contrarius Investment Management St. Helier, Jersey $1.76B AUM 35.87% 1-Year Est. Return
PRO
Pensioenfonds Rail & OV Utrecht, Netherlands $1.44B AUM 23.73% 1-Year Est. Return
GFS
GYL Financial Synergies West Hartford, Connecticut $1.33B AUM 34.46% 1-Year Est. Return
ECM
Ensemble Capital Management San Francisco, California $1.18B AUM 41.81% 1-Year Est. Return
CIP
Chartwell Investment Partners Berywn, Pennsylvania $2.91B AUM 40.48% 1-Year Est. Return
SEC
Seven Eight Capital New York $1.11B AUM 29.48% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Boxer Capital's Q1 2024 Portfolio in Review

As of Q1 2024, Boxer Capital held 65 positions worth $2.02B, up 0.92% from $2.01B the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Boxer Capital withdrew a net $139M in Q1 2024, closing 6 positions and reducing 4 holdings. Its most notable exit was Mirati Therapeutics, Inc. Common Stock, an estimated $188M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier.

Against the trend, Boxer Capital opened a new position in Amylyx Pharmaceuticals worth $4.26M.

  • Boxer Capital's largest Q1 2024 buy was Amylyx Pharmaceuticals: 1,500,000 shares worth $4.26M.
  • Boxer Capital added most to Fate Therapeutics in Q1 2024, an estimated $47.8M increase.
  • Boxer Capital's biggest Q1 2024 reduction was argenx, cutting an estimated $23.2M.
  • Boxer Capital fully exited Mirati Therapeutics, Inc. Common Stock in Q1 2024, selling an estimated $188M.
  • Boxer Capital's ten largest holdings make up 54% of its $2.02B portfolio in Q1 2024.
  • Boxer Capital opened 13 new positions and closed 6 in Q1 2024.
  • Boxer Capital's portfolio value rose 0.92% quarter-over-quarter to $2.02B.

Based on Boxer Capital's 13F filing for Q1 2024, filed 15 May 2024.